Skip to main content.

Federal, local officials hopeful for 'new era' in valley fever

Federal Agencies Get Involved

Fellowship Story Showcase

Federal, local officials hopeful for 'new era' in valley fever

The Reporting on Health Collaborative involves The Californian, the Merced Sun-Star, Radio Bilingue in Fresno, The Record in Stockton, Valley Public Radio in Fresno and Bakersfield, Vida en el Valle in Fresno, the Voice of OC in Santa Ana and Center for Health Journalism Digital. It's an initiative of Health Journalism Fellowships at the University of Southern California's Annenberg School for Communication and Journalism.

Dr. Royce Johnson of Kern Medical Center, Dr. Thomas Frieden of the Centers for Disease Control and Prevention, and Dr. Francis Collins of the National Institutes of Health address the crowd of a two-day symposium. Henry A. Barrios/The Californian

Reporting on Health Collaborative
Wednesday, September 25, 2013
BY RACHEL COOK, Reporting on Health Collaborative

Many questions about valley fever remained unanswered Tuesday afternoon as public health officials, physicians and politicians finished a two-day symposium on the disease, but officials and doctors alike were hopeful that the summit will be a turning point in the fight against valley fever.

Two of the country’s top public health officials said they were leaving Bakersfield with a greater understanding of the disease’s burden and a renewed commitment to solving its mysteries.

“You all here in Bakersfield and in Arizona have been laboring for (all of) these years to try to come up with answers and we are proud to be here, to be your partners in a new era here, which I think this symposium really serves as a marker for about how we might go forward,” Dr. Francis Collins, director for the National Institutes of Health, told the audience during a morning session.

“My real big impression from the two days has been what a heavy burden (valley fever) is for individuals,” said Dr. Thomas Frieden, director of the Centers for Disease Control and Prevention, noting that some patients require lifelong treatment. “It really brought home to me just how serious the problem is.” 

Tuesday’s symposium was packed with quick presentations by more than two dozen speakers on everything from valley fever in pets to research detecting what patches of earth harbor valley fever. The disease is caused by inhaling the spores of a fungus that dwells in soil. Valley fever is common in parts of the southwest and has also been found in Central and South America. Most people who have valley fever — also known as coccidioidomycosis — will never know they have it, but some develop a flu-like illness and a smaller number of patients become seriously ill. A CDC study found that valley fever was an underlying or contributing cause of more than 3,000 deaths from 1990-2008, about 170 a year.

Presenters talked about a drug — Nikkomycin Z — that could potentially cure valley fever in humans, instead of just stabilize the fungus like current medications.

“We think this (drug) just for valley fever, can have sales of $250 million a year,”said David Larwood, CEO of the company Valley Fever Solutions, a drug company spun off by University of Arizona researchers. 

An official from the Arizona Department of Health Services spoke about how that state, which has about two-thirds of the reported U.S. cases of valley fever, works to raise awareness among patients and doctors, and hosts an annual awareness week. U.S. Rep. David Schweikert, a Republican representing the Phoenix-Scottsdale area, said he and fellow Congressman Kevin McCarthy, R-Bakersfield, have been plotting on how to get all the different parties concerned about valley fever to communicate and collaborate across state lines.

Another physician suggested that California require that health workers, including doctors and nurse practitioners, complete medical education on valley fever in order to be licensed. 

A physician from California Correctional Health Care Services said a skin test would greatly help the agency better identify inmates at risk of becoming infected with valley fever. McCarthy, who organized the symposium, said he and others will continue pressing the U.S. Food and Drug Administration to waive the fee for a skin test — developed by a San Diego company — in order to get it into the market.

Whether or not all of the promising prospects raised during the symposium come to fruition, valley fever advocates said attendees were energized to keep pushing for answers.

“I am more excited. I think (the symposium) surpassed all expectations,” said McCarthy, who hosted and organized the symposium.

A major success, McCarthy said, was Monday’s announcement that the NIH and CDC will collaborate on a randomized controlled trial focusing on community-acquired pneumonia, the most common presentation of valley fever, and the best treatment for valley fever. The NIH will fund the study, which hopes to enroll about 1,000 people and will require millions of dollars and multiple years to complete, Collins said Monday.

“To accomplish that now has been tremendous,” McCarthy said. “It just shows the awareness of valley fever and the need for (the study) has won on its merit.”

He said a combination of private and public funding will be needed to achieve the goals around valley fever. 

“We have to watch how we fund government but we need to prioritize the money that we have. I mean there’s nothing better than putting (those) resources into science,” McCarthy said, pointing out that the disease has major costs to individual patients and the prison system.

“With a skin test, how much more would we save? With a vaccine how much more would we save?” he asked.

Dr. Paul Krogstad, a professor of pediatrics and pharmacology at the David Geffen School of Medicine at UCLA, said physicians are less interested in pursuing careers in academic medicine because funding is scarce, but Krogstad hoped the attention from the symposium may attract more bright minds to study valley fever. 

“If only a few people with interest in fungal infections, mycology, drug development took an interest in valley fever, things could change,” Krogstad said.

Dr. Tom Chi

ller, deputy chief of the CDC’s Mycotic Diseases Branch, said the disease is even more under-diagnosed in South and Central America, where testing is limited. Understanding more about who to treat for valley fever and when to treat them will help people in those areas as well, he said.

“I think that this (push) is really the chance for a new beginning ... toward a more aggressive strategy,” Chiller said. “We need to go on the offensive against this disease so that we can actually try to prevent people from being sick, severely sick.”  

Chiller said the first step is an awareness campaign with solid materials and a strategy for working with public health departments at the county and state level so they are equipped to spread education about the disease. The best offense against valley fever is awareness, Chiller said, pointing to an Arizona study that showed that people were more likely to ask to be tested for valley fever if they knew about the disease.

“Have forums like this, you know, maybe a valley fever awareness week in Bakersfield every year,” he said. “Something that reoccurs. Let’s get a strategy, let’s get something on the calendar, let’s get something that continues to happen.

“The people that are passionate about (valley fever) are not going to let (the momentum) die. They’re going to continue to make noise and I think we need to harness that noise and put it into a more strategic plan about how we get the message out.”

About This Series

This project results from an innovative reporting venture – the Center for Health Journalism Collaborative – which currently involves the Bakersfield Californian, Radio Bilingüe in Fresno, Valley Public Radio in Fresno and Bakersfield, Vida en el Valle in Fresno, Hanford Sentinel, the Voice of OC in Santa Ana, the Arizona Daily Star in Tucson, La Estrella de Tucsón and the Center for Health Journalism. The collaborative is an initiative of the Center for Health Journalism at the University of Southern California’s Annenberg School for Communication and Journalism.


Valley fever medication poses added risk for pregnant women

Research suggests an alarming link between a common drug used for valley fever and birth defects. The disease also tends to be more severe in pregnant women.

Legislation caps momentous year in battle against valley fever

Recently signed legislation capped a big year for efforts to combat a regional disease long overlooked by lawmakers.

For valley fever survivors, a growing need: wigs

The antifungal drugs used to treat valley fever can cause hair loss. With the number of valley fever cases on the rise, a wig shop in Bakersfield, Calif., is helping women feel better about themselves.

California budget boosts funding for valley fever

The budget includes $8 million for research and outreach into the disease, caused by inhaling spores that grow in arid soil.

Three valley fever bills sail through committee, one pulled by sponsor

Facing pushback from the medical community, California Assemblyman Vince Fong withdrew a bill late last month that would have required doctors to order specific types of lab tests when they suspect valley fever.

Assemblymen ask state for $7 million in fight against valley fever to fuel research, spread awareness

Bakersfield Assemblymen Vince Fong and Rudy Salas submitted a $7 million budget proposal that, if approved, would be the largest amount of money California has ever designated to research and raise awareness of the disease.

One year after federal health officials launch first-of-its-kind valley fever drug trial, few have enrolled

Just 48 people have signed up across California and Arizona for a new clinical trial of Fluconazole, an antifungal drug used to treat valley fever. That's far fewer than officials had expected.

Bakersfield legislators ask state for $3M in fight against valley fever

Bakersfield lawmakers requested $3 million in the state budget last week to research treatments and conduct outreach for valley fever.

В интеренете нашел интересный web-сайт с информацией про Женские возбудители виагра таблетки